Recent News

• 02.04.2026 - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
• 01.29.2026 - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
• 12.29.2025 - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
• 11.25.2025 - Unicycive Therapeutics to Participate in Upcoming Investor Events in December
• 11.12.2025 - Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
• 11.03.2025 - Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
• 10.30.2025 - Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
• 10.28.2025 - Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Recent Filings

• 01.23.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 8-K Current report
• 11.12.2025 - 8-K Current report
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]